<DOC>
	<DOCNO>NCT02043808</DOCNO>
	<brief_summary>The objective ass safety effectiveness new dabigatran warfarin patient diagnose NVAF US DoD population .</brief_summary>
	<brief_title>The Safety Effectiveness Warfarin Dabigatran Prescribed Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage</brief_title>
	<detailed_description>Study Design : Retrospective</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion : Patients must continuously enrol health plan preindex period ; Patients must least one inpatient , one physician office visit , emergency room visit diagnosis AF ( ICD9CM diagnosis code : 427.31in position ) index date preindex period ; Patients must prescription dabigatran warfarin ( first prescription index date ) ; Patients must treatment naive OAC use prior first dabigatran warfarin prescription ; Aged 1889 index date ; Exclusion criterion : Patients valvular procedure relate baseline AF diagnosis exclude ; Patients transient cause AF hyperthyroidism , cardiac surgery , pericarditis , mycoarditis , pulmonary embolism within 3 month prior first diagnosis AF ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>